NCT06930352 2026-03-13Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyOhio State University Comprehensive Cancer CenterPhase 2 Not yet recruiting70 enrolled